Miner Company
Biotech firm Odyssey targets $810 million in valuation in US IPO
Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States.
Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in its initial public offering in the United States.